Avricore Health Inc. Files June 2025 6-K Report

Ticker: AVCRF · Form: 6-K · Filed: Jul 11, 2025 · CIK: 1355736

Avricore Health INC. 6-K Filing Summary
FieldDetail
CompanyAvricore Health INC. (AVCRF)
Form Type6-K
Filed DateJul 11, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: reporting, foreign-private-issuer, corporate-history

TL;DR

AVRICORE HEALTH (AVRX) filed its June 6-K, confirming 40-F annual report status.

AI Summary

Avricore Health Inc. filed a Form 6-K for the month of June 2025, reporting as a foreign private issuer. The company, formerly known as Vanc Pharmaceuticals Inc., NUVA Pharmaceuticals Inc., and ALDA Pharmaceuticals Corp., is incorporated in A1 and has its principal executive offices at 1120-789 West Pender St, Vancouver, BC, V6C 1H2. The filing indicates the company is submitting its annual reports under Form 40-F.

Why It Matters

This filing provides routine updates for Avricore Health Inc. as a foreign private issuer, informing investors about their reporting status and corporate history.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

This Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of June 2025.

What is Avricore Health Inc.'s SEC file number?

Avricore Health Inc.'s SEC file number is 000-51848.

Which form does Avricore Health Inc. use for its annual reports?

Avricore Health Inc. indicates it files its annual reports under cover of Form 40-F.

What is the principal executive office address for Avricore Health Inc.?

The principal executive office address is 1120-789 West Pender St, Vancouver, BC, V6C 1H2.

What were some of Avricore Health Inc.'s former company names?

Avricore Health Inc. was formerly known as Vanc Pharmaceuticals Inc., NUVA Pharmaceuticals Inc., and ALDA Pharmaceuticals Corp.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on July 11, 2025 regarding Avricore Health Inc. (AVCRF).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing